MoonLake Immunotherapeutics (MLTX) Cash from Financing Activities (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $30.6 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 58.09% year-over-year to $30.6 million in Q1 2026; TTM through Mar 2026 was $103.5 million, a 40.93% increase from a year earlier, with the FY2025 full-year figure at $146.0 million, up 184.53% from the prior year.
• Cash from Financing Activities eased to $30.6 million in Q1 2026 per MLTX's latest filing, from $72.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $451.3 million in Q2 2023 and bottomed at $3791.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $29.5 million (2023), against an average of $68.9 million.
• Across the five-year window, Cash from Financing Activities tumbled 99.99% in 2022 and soared 749462.31% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $3791.0 in 2022, then surged by 749462.31% to $28.4 million in 2023, then sank by 99.47% to $151000.0 in 2024, then soared by 47843.71% to $72.4 million in 2025, then slumped by 57.67% to $30.6 million in 2026.
• Per Business Quant, the three latest MLTX Cash from Financing Activities figures stand at $30.6 million (Q1 2026), $72.4 million (Q4 2025), and $480000.0 (Q3 2025).